Colon Targeting Drug Delivery Global Market Report 2025

The colon targeting drug delivery market size has grown strongly in recent years. It will grow from$1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth during the historic period can be attributed to the rising prevalence of colorectal diseases, an increased focus on localized drug delivery, the need for improved patient compliance, and the emergence of biologics and peptides in treatment options.

The colon targeting drug delivery market size is expected to see strong growth in the next few years. It will grow to$2.07 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to the development of stimuli-responsive and nanotechnology-based delivery systems, the expansion of contract research and manufacturing services, regulatory agencies providing incentives and faster approval pathways, and the targeted delivery of biologics and biosimilars. Key trends during this period include advancements in pH-responsive systems, the integration of personalized medicine, the use of AI and digital tools in formulation design, and an increasing focus on oral colon delivery.

The increasing prevalence of gastrointestinal diseases is expected to drive the expansion of the colon targeting drug delivery market. Gastrointestinal diseases, which affect the digestive system including the stomach, intestines, and related organs, are becoming more common due to unhealthy dietary habits, such as high consumption of processed foods and low fiber intake. These habits disrupt gut health and digestion, leading to a rise in conditions such as inflammatory bowel disease (IBD). Colon targeting drug delivery is being used to ensure that drugs are precisely released at the site of inflammation or infection, increasing therapeutic effectiveness and minimizing systemic side effects. For example, in June 2023, Crohn's and Colitis Canada reported that the number of people affected by inflammatory bowel disease is projected to rise from 322,600 in 2023 (0.8% of the population) to 470,000 by 2035 (1.1% of the population). This growing prevalence of gastrointestinal diseases is driving demand for colon-targeting drug delivery solutions.

Companies in the colon targeting drug delivery market are focusing on developing advanced solutions that improve targeted drug release, enhance therapeutic efficacy, and reduce side effects. One such innovation is the development of functional oral dosage forms, which are designed to protect active pharmaceutical ingredients (APIs) from degradation in the upper gastrointestinal tract, ensuring their controlled release in the colon. In September 2024, Evonik Industries AG, a Germany-based specialty chemicals company, launched EUDRACAP Functional, a ready-to-fill capsule technology that enables the precise delivery of oral drugs to the colon. This technology uses pH-sensitive polymers that dissolve only at specific intestinal pH levels, ensuring that the API reaches the colon intact. By supporting the oral delivery of complex APIs such as peptides and probiotics, EUDRACAP Functional helps develop patient-friendly therapies for chronic gastrointestinal disorders, offering greater accuracy and reduced systemic exposure.

In October 2023, Roche Holding AG, a Switzerland-based healthcare company, acquired Telavant Holding Inc. for $7.1 billion. This acquisition strengthens Roche's position in the colon targeting drug delivery market by integrating Telavant's RVT-3101, a drug aimed at treating inflammatory bowel diseases. Telavant Holding Inc., a US-based biopharmaceutical company, specializes in developing therapies for gastrointestinal disorders. This strategic acquisition enhances Roche's ability to provide innovative treatments for gastrointestinal diseases, further advancing their portfolio in the field of colon-targeting drug delivery.

Major players in the colon targeting drug delivery market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Lonza Pharma AG, Ferring Pharmaceuticals Company Limited, Salix Pharmaceuticals Ltd., Tillotts Pharma AG, BDD Pharma Ltd., and Tharimmune Inc.

North America was the largest region in the colon targeting drug delivery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in colon targeting drug delivery report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the colon targeting drug delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Colon targeting drug delivery refers to a specialized system designed to release therapeutic agents directly in the colon, enhancing treatment effectiveness for local diseases such as inflammatory bowel disease and colorectal cancer. This approach minimizes systemic side effects and improves patient compliance.

The main dosage forms for colon-targeted drug delivery include tablets, capsules, microspheres, nanoparticles, and others. Tablets are solid, compressed forms of medication intended for oral intake. In colon-targeted delivery, these tablets are often coated with materials that prevent dissolution in the stomach or small intestine, ensuring the drug is released specifically in the colon. Various technologies are used in these systems, including pH-sensitive systems, time-dependent systems, microbially triggered systems, pressure-controlled systems, and others. These systems are applied in treating conditions such as inflammatory bowel disease, colorectal cancer, infectious diseases, and more. They are primarily utilized by end users such as hospitals, clinics, research institutes, and other healthcare settings.

The colon targeted drug delivery market research report is one of a series of new reports that provides colon targeted drug delivery market statistics, including the colon targeted drug delivery industry's global market size, regional shares, competitors with a colon targeted drug delivery market share, detailed colon targeted drug delivery market segments, market trends and opportunities, and any further data you may need to thrive in the colon targeted drug delivery industry. This colon targeted drug delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The colon targeting drug delivery market includes revenues earned by entities by providing services such as formulation development, preformulation studies, drug delivery technology licensing, coating and encapsulation services, and in-vitro release testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.